应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
RGEN Repligen Corporation
已收盘 11-19 16:00:00 EST
170.29
-2.38
-1.38%
盘后
170.29
+0.00
0.00%
19:30 EST
最高
178.85
最低
168.94
成交量
88.06万
今开
173.69
昨收
172.67
日振幅
5.74%
总市值
108.86亿
流通市值
103.60亿
总股本
6,392万
成交额
1.52亿
换手率
1.45%
流通股本
6,084万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读|Repligen Corporation盘中上涨5.14%,公司更新利润率与并购增厚预期
行情直击 · 11-19 00:16
异动解读|Repligen Corporation盘中上涨5.14%,公司更新利润率与并购增厚预期
异动解读|Repligen Corporation盘中下跌8.31%,10亿美元可转债发行压制股价
行情直击 · 10-31
异动解读|Repligen Corporation盘中下跌8.31%,10亿美元可转债发行压制股价
异动解读|Repligen Corporation盘中上涨5.27%,RBC上调目标价至200美元
行情直击 · 10-29
异动解读|Repligen Corporation盘中上涨5.27%,RBC上调目标价至200美元
财报前瞻 | Repligen Corporation本季度营收预计小幅增长,机构观点偏谨慎增持
财报Agent · 10-20
财报前瞻 | Repligen Corporation本季度营收预计小幅增长,机构观点偏谨慎增持
异动解读|Repligen盘中下跌6.33%,完成收购BioLife Solutions后市场反应谨慎
行情直击 · 10-07
异动解读|Repligen盘中下跌6.33%,完成收购BioLife Solutions后市场反应谨慎
异动解读 | Repligen Corporation盘中大涨17.38%,Q2业绩全面超预期并上调全年指引
异动解读 · 07-28
异动解读 | Repligen Corporation盘中大涨17.38%,Q2业绩全面超预期并上调全年指引
异动解读|Repligen盘中上涨15.35%,Q2业绩大超预期且上调全年指引
行情直击 · 07-28
异动解读|Repligen盘中上涨15.35%,Q2业绩大超预期且上调全年指引
若交易在特定情况下终止,Biolife或需向Repligen支付5900万美元终止费
美股速递 · 07-22
若交易在特定情况下终止,Biolife或需向Repligen支付5900万美元终止费
Repligen斥资15亿美元收购BioLife,以扩大细胞治疗业务
老虎资讯综合 · 07-22
Repligen斥资15亿美元收购BioLife,以扩大细胞治疗业务
Repligen将收购BioLife Solutions,通过市场领先的生物保存介质拓展其细胞疗法能力
美股速递 · 07-22
Repligen将收购BioLife Solutions,通过市场领先的生物保存介质拓展其细胞疗法能力
异动解读|Repligen Corporation盘中上涨6.57%,报147.52美元
行情直击 · 06-26
异动解读|Repligen Corporation盘中上涨6.57%,报147.52美元
Repligen Corporation盘中异动 快速下跌5.17%报147.65美元
市场透视 · 2025-03-10
Repligen Corporation盘中异动 快速下跌5.17%报147.65美元
Repligen Corporation盘中异动 股价大跌5.16%报147.37美元
市场透视 · 2025-03-04
Repligen Corporation盘中异动 股价大跌5.16%报147.37美元
Repligen Corporation盘中异动 下午盘股价大涨5.01%
市场透视 · 2025-02-25
Repligen Corporation盘中异动 下午盘股价大涨5.01%
小摩:维持Repligen(RGEN.US)评级,由增持调整至增持评级, 目标价由190.00美元调整至200.00美元。
金融界 · 2025-02-21
小摩:维持Repligen(RGEN.US)评级,由增持调整至增持评级, 目标价由190.00美元调整至200.00美元。
加拿大投资银行集团:维持Repligen(RGEN.US)评级,由持有调整至持有评级, 目标价由165.00美元调整至170.00美元。
金融界 · 2025-02-21
加拿大投资银行集团:维持Repligen(RGEN.US)评级,由持有调整至持有评级, 目标价由165.00美元调整至170.00美元。
异动解读 | Repligen公司2024年Q4财报超预期,股价盘中涨逾9%
异动解读 · 2025-02-21
异动解读 | Repligen公司2024年Q4财报超预期,股价盘中涨逾9%
异动解读 | Repligen公司盘前大涨9.47%,业绩超预期带来市场利好
异动解读 · 2025-02-20
异动解读 | Repligen公司盘前大涨9.47%,业绩超预期带来市场利好
Repligen 2024年第四季度调整后每股收益0.44美元,超出预期的0.41美元,销售额为1.6755亿美元,低于预期的1.6767亿美元
财报速递 · 2025-02-20
Repligen 2024年第四季度调整后每股收益0.44美元,超出预期的0.41美元,销售额为1.6755亿美元,低于预期的1.6767亿美元
Repligen Corporation盘中异动 下午盘急速下跌5.10%
市场透视 · 2025-01-30
Repligen Corporation盘中异动 下午盘急速下跌5.10%
加载更多
公司概况
公司名称:
Repligen Corporation
所属市场:
NASDAQ
上市日期:
--
主营业务:
Repligen Corporation成立于1981年5月。该公司是生物制剂生产关键产品的领先供应商。公司根据长期供应协议为主要生命科学公司生产Protein A,同时也直接向终端用户销售产品,供其生产工艺使用。公司还将其在生物制品开发方面的专业知识应用于SecreFlo的研发。SecreFlo是公司正在开发的一种合成人激素,旨在作为一种新型显像剂用于诊断胰腺炎以及潜在的多种胰腺疾病。该公司目前还有两项针对弗里德赖希氏共济失调和脊髓性肌萎缩症的早期中枢神经系统罕见病项目正在进行中,并已进入I期临床试验阶段。此外,该公司已将部分知识产权授权给Bristol-Myers Squibb Company,并从该公司在美国销售的Orencia产品净销售额中获得特许权使用费。
发行价格:
--
{"stockData":{"symbol":"RGEN","market":"US","secType":"STK","nameCN":"Repligen Corporation","latestPrice":170.29,"timestamp":1795122000000,"preClose":172.67,"halted":0,"volume":880555,"hourTrading":{"tag":"盘后","latestPrice":170.29,"preClose":170.29,"latestTime":"19:30 EST","volume":135831,"amount":23130660.99,"timestamp":1795134606297,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01378351769270861,"floatShares":60840212,"shares":63923738,"eps":-0.21,"marketStatus":"已收盘","change":-2.38,"latestTime":"11-19 16:00:00 EST","open":173.69,"high":178.85,"low":168.943,"amount":151784637.87565,"amplitude":0.057375,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.21,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1795165200000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":172.67,"preHourTrading":{"tag":"盘前","latestPrice":173.5,"preClose":172.67,"latestTime":"09:05 EST","volume":458,"amount":79113.9811,"timestamp":1795097109416,"change":0.83,"changeRate":0.004807,"amplitude":0.013494},"postHourTrading":{"tag":"盘后","latestPrice":170.29,"preClose":170.29,"latestTime":"19:30 EST","volume":135831,"amount":23130660.99,"timestamp":1795134606297,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.112347,"impliedVol":0.5087,"impliedVolPercentile":0.5378},"requestUrl":"/m/hq/s/RGEN","defaultTab":"news","newsList":[{"id":"1117347188","title":"异动解读|Repligen Corporation盘中上涨5.14%,公司更新利润率与并购增厚预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1117347188","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117347188?lang=zh_cn&edition=full","pubTime":"2026-11-19 00:16","pubTimestamp":1795018571,"startTime":"0","endTime":"0","summary":"11月19日,Repligen Corporation盘中上涨5.14%,报170.57美元,成交额6202.12万美元。消息面上,公司最新表示目标调整后EBITDA利润率约30%,并重申BioLife收购首年仍有望带来超过0.05美元的增厚,强化了市场对并购整合与盈利修复的预期。进一步看,公司预计BioLife全年收入约1.14亿美元,明显高于2024年的7500万美元;此前公司还在10月完成对BioLife的收购,并在10月下旬公布三季度调整后EPS为0.53美元、营收2.093亿美元,双双高于预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Repligen盘中大涨,并购增厚预期升温","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151841858","title":"异动解读|Repligen Corporation盘中下跌8.31%,10亿美元可转债发行压制股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1151841858","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151841858?lang=zh_cn&edition=full","pubTime":"2026-10-31 00:17","pubTimestamp":1793377032,"startTime":"0","endTime":"0","summary":"10月31日,Repligen Corporation盘中下跌8.31%,报173.56美元,成交额3.83亿美元。本次异动的直接催化来自公司宣布发行总额10亿美元、票息0.25%、2031年到期的可转换高级票据,稀释预期与融资压力压制股价表现。具体看,其中5.414亿美元新票据将置换约4.568亿美元原有2028年到期1.00%可转债,另有4.586亿美元为现金认购;初始转股价为226.37美元,较10月29日收盘价溢价20%。公司拟动用约1.2亿美元以188.64美元回购股份,其余资金用于营运资本、并购及一般企业用途。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"发行10亿美元可转债,Repligen股价承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150052931","title":"异动解读|Repligen Corporation盘中上涨5.27%,RBC上调目标价至200美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1150052931","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150052931?lang=zh_cn&edition=full","pubTime":"2026-10-29 00:13","pubTimestamp":1793203988,"startTime":"0","endTime":"0","summary":"10月29日,Repligen Corporation盘中上涨5.27%,报185.07美元,成交额7031.98万美元。本次异动的直接催化来自机构上调目标价。最新消息显示,RBC将公司目标价由185美元上调至200美元,并维持跑赢大盘评级。此前公司第三季度业绩亦提供支撑:调整后每股收益0.53美元,高于市场预期的0.46美元;营收2.093亿美元,高于预期的2.067亿美元;全年调整后每股收益指引收窄至2.05至2.09美元,区间中值高于市场预期。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Repligen盘中异动,RBC上调目标价至200美元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188451701","title":"财报前瞻 | Repligen Corporation本季度营收预计小幅增长,机构观点偏谨慎增持","url":"https://stock-news.laohu8.com/highlight/detail?id=1188451701","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188451701?lang=zh_cn&edition=full","pubTime":"2026-10-20 10:02","pubTimestamp":1792461773,"startTime":"0","endTime":"0","summary":"Repligen Corporation将于2026年10月27日发布最新季度财报,市场关注收入增速与利润率修复节奏及其对全年指引的影响。市场一致预期本季度公司营收为2.07亿美元,同比增长13.94%;调整后每股收益为0.46美元,同比增长10.11%;息税前利润为2,916.47万美元,同比增长19.87%。上季度公司实现营收2.04亿美元,同比增长11.93%;毛利率53.91%;归属于母公司股东的净利润为500.80万美元,净利率2.45%;调整后每股收益为0.54美元,同比增长45.95%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | Repligen Corporation本季度营收预计小幅增长,机构观点偏谨慎增持","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198295066","title":"异动解读|Repligen盘中下跌6.33%,完成收购BioLife Solutions后市场反应谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1198295066","media":"行情直击","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198295066?lang=zh_cn&edition=full","pubTime":"2026-10-07 00:27","pubTimestamp":1791304027,"startTime":"0","endTime":"0","summary":"10月6日,Repligen Corporation盘中下跌6.33%,报177.505美元/股,成交额1.24亿美元。消息面上,公司正式宣布完成对BioLife Solutions的收购,交易估值约15亿美元,以现金加股票方式支付,旨在拓展其在细胞治疗市场的业务布局。根据此前协议,BioLife股东每股可获得11.25美元现金及0.1442股Repligen股票,对应每股估值约31美元。此次收购使Repligen获得BioLife在细胞保存技术、细胞处理工具及高利润率耗材方面的能力,有望完善先进疗法供应链。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Repligen完成收购,股价承压走低","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173519787","title":"异动解读 | Repligen Corporation盘中大涨17.38%,Q2业绩全面超预期并上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1173519787","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173519787?lang=zh_cn&edition=full","pubTime":"2026-07-28 22:30","pubTimestamp":1785249011,"startTime":"0","endTime":"0","summary":"Repligen Corporation(RGEN)今日盘中大涨17.38%,引发市场高度关注。消息面上,公司于今日盘前公布了第二季度财报,业绩全面超出市场预期。财报显示,公司Q2调整后每股收益为0.54美元,远超市场预期的0.45美元,同比大增45.95%;营收达2.041亿美元,高于预期的2.015亿美元,同比增长11.9%。此外,公司还上调了全年业绩指引,预计调整后每股收益为2.03至2.09美元(此前为1.97至2.05美元),营收为8.13亿至8.35亿美元(此前为8.03亿至8.33亿美元),均高于分析师预期。强劲的财报数据及乐观的前景展望共同推动了股价的盘中飙升。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108189033","title":"异动解读|Repligen盘中上涨15.35%,Q2业绩大超预期且上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1108189033","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108189033?lang=zh_cn&edition=full","pubTime":"2026-07-28 22:29","pubTimestamp":1785248963,"startTime":"0","endTime":"0","summary":"7月28日,Repligen盘中上涨15.35%,报149.47美元/股,成交额9878.79万美元。消息面上,公司当日盘前公布第二季度财报,业绩全面超出市场预期。Q2调整后每股收益0.54美元,远超市场预期的0.45美元,同比大增45.95%;营收2.041亿美元,高于预期的2.015亿美元,同比增长11.9%。Repligen是全球生物制剂生产关键设备及耗材的领先供应商,产品覆盖单克隆抗体、重组蛋白、疫苗及细胞与基因疗法等生物制药工艺领域。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183199218","title":"若交易在特定情况下终止,Biolife或需向Repligen支付5900万美元终止费","url":"https://stock-news.laohu8.com/highlight/detail?id=1183199218","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183199218?lang=zh_cn&edition=full","pubTime":"2026-07-22 21:04","pubTimestamp":1784725473,"startTime":"0","endTime":"0","summary":"根据相关协议条款,在某些特定情形下,如果交易被终止,Biolife可能被要求向Repligen Corporation支付一笔高达5900万美元的终止费用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0757428866.USD","RGEN","LU0106261612.USD","LU0205194284.USD","LU0012050646.USD","LU1815336091.USD","BK4121","LU0205193047.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169933349","title":"Repligen斥资15亿美元收购BioLife,以扩大细胞治疗业务","url":"https://stock-news.laohu8.com/highlight/detail?id=1169933349","media":"老虎资讯综合","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169933349?lang=zh_cn&edition=full","pubTime":"2026-07-22 20:15","pubTimestamp":1784722547,"startTime":"0","endTime":"0","summary":"Repligen Corp周三表示,将以现金加股票方式收购BioLife Solutions,交易估值约为15亿美元,以扩大这家制药设备供应商在快速增长的细胞治疗市场的业务布局。此次收购将使Repligen获得BioLife在细胞保存技术方面的能力,可用于整个生产流程及供应链中的细胞保存,同时还将获得其细胞处理工具产品组合以及利润率较高的耗材业务。根据交易条款,BioLife股东每持有一股BioLife股票,将获得11.25美元现金以及0.1442股Repligen股票,对应BioLife每股估值约为31美元,较该公司上一交易日收盘价溢价约6.2%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/7cb15f3cc7d8054b7829af808afcb782","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/7cb15f3cc7d8054b7829af808afcb782"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Repligen斥资15亿美元收购BioLife,以扩大细胞治疗业务","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGEN","BLFS"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1174553516","title":"Repligen将收购BioLife Solutions,通过市场领先的生物保存介质拓展其细胞疗法能力","url":"https://stock-news.laohu8.com/highlight/detail?id=1174553516","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174553516?lang=zh_cn&edition=full","pubTime":"2026-07-22 18:02","pubTimestamp":1784714521,"startTime":"0","endTime":"0","summary":"Repligen Corporation(RGEN)已同意收购BioLife Solutions Inc.(BLFS),此举旨在通过整合后者市场领先的生物保存介质产品,显著增强其在细胞治疗领域的技术与业务能力。这项交易将Repligen在生物工艺领域的专长与BioLife Solutions在细胞与基因治疗低温保存解决方案方面的领导地位相结合,预计将创造更完整的供应链产品组合,服务于快速增长的先进疗法市场。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLFS","LU0757428866.USD","BK4121","LU1169589451.USD","LU0012050646.USD","LU0205194284.USD","LU1815336091.USD","BK4198","LU0205193047.USD","LU0106261612.USD","LU1169590202.USD","RGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134464808","title":"异动解读|Repligen Corporation盘中上涨6.57%,报147.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1134464808","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134464808?lang=zh_cn&edition=full","pubTime":"2026-06-26 00:15","pubTimestamp":1782404130,"startTime":"0","endTime":"0","summary":"6月26日,Repligen Corporation盘中上涨6.57%,报147.52美元/股,成交额1.05亿美元。Repligen Corporation所在的生命科学工具和服务行业中,整体表现强势,个股中,Techne Corporation涨19.7%,赛默飞世尔涨3.78%,丹纳赫涨3.12%,Tempus AI涨5.04%,Illumina涨3.25%。Repligen Corporation是生物制剂生产关键产品的领先供应商,专注于生物工艺技术,为主要生命科学公司生产Protein A等核心产品,同时直接向终端用户销售生物加工设备和用品。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518827601","title":"Repligen Corporation盘中异动 快速下跌5.17%报147.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518827601","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518827601?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:52","pubTimestamp":1741614761,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时52分,Repligen Corporation股票出现异动,股价急速跳水5.17%。截至发稿,该股报147.65美元/股,成交量7.3314万股,换手率0.13%,振幅2.90%。Repligen Corporation股票所在的医疗设备行业中,整体跌幅为1.40%。Repligen Corporation公司简介:Repligen 总部位于马萨诸塞州沃尔瑟姆,是一家全球生命科学公司,开发和销售用于制造生物药物的生物加工设备和用品,包括单克隆抗体、重组蛋白、疫苗以及细胞和基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310215241abf30469&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310215241abf30469&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RGEN","LU1815336091.USD","LU0757428866.USD","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517605707","title":"Repligen Corporation盘中异动 股价大跌5.16%报147.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517605707","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517605707?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:47","pubTimestamp":1741103262,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日23时47分,Repligen Corporation股票出现波动,股价大幅下跌5.16%。截至发稿,该股报147.37美元/股,成交量11.4499万股,换手率0.20%,振幅4.70%。Repligen Corporation股票所在的医疗设备行业中,整体跌幅为1.24%。Repligen Corporation公司简介:Repligen 总部位于马萨诸塞州沃尔瑟姆,是一家全球生命科学公司,开发和销售用于制造生物药物的生物加工设备和用品,包括单克隆抗体、重组蛋白、疫苗以及细胞和基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304234742a25f19d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304234742a25f19d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","LU0757428866.USD","LU1815336091.USD","RGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514703863","title":"Repligen Corporation盘中异动 下午盘股价大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514703863","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514703863?lang=zh_cn&edition=full","pubTime":"2025-02-25 04:06","pubTimestamp":1740427594,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日04时06分,Repligen Corporation股票出现波动,股价快速拉升5.01%。截至发稿,该股报166.96美元/股,成交量47.4486万股,换手率0.85%,振幅5.20%。Repligen Corporation股票所在的医疗设备行业中,整体涨幅为0.23%。Repligen Corporation公司简介:Repligen 总部位于马萨诸塞州沃尔瑟姆,是一家全球生命科学公司,开发和销售用于制造生物药物的生物加工设备和用品,包括单克隆抗体、重组蛋白、疫苗以及细胞和基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502250406349891370c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502250406349891370c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0757428866.USD","BK4121","RGEN","LU1815336091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513097291","title":"小摩:维持Repligen(RGEN.US)评级,由增持调整至增持评级, 目标价由190.00美元调整至200.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513097291","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513097291?lang=zh_cn&edition=full","pubTime":"2025-02-21 23:22","pubTimestamp":1740151334,"startTime":"0","endTime":"0","summary":"小摩:维持Repligen(RGEN.US)评级,由增持调整至增持评级, 目标价由190.00美元调整至200.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/21232248320493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513262262","title":"加拿大投资银行集团:维持Repligen(RGEN.US)评级,由持有调整至持有评级, 目标价由165.00美元调整至170.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513262262","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513262262?lang=zh_cn&edition=full","pubTime":"2025-02-21 20:40","pubTimestamp":1740141632,"startTime":"0","endTime":"0","summary":"加拿大投资银行集团:维持Repligen(RGEN.US)评级,由持有调整至持有评级, 目标价由165.00美元调整至170.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/21204048318756.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103076426","title":"异动解读 | Repligen公司2024年Q4财报超预期,股价盘中涨逾9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1103076426","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103076426?lang=zh_cn&edition=full","pubTime":"2025-02-21 03:48","pubTimestamp":1740080910,"startTime":"0","endTime":"0","summary":"上市生物科技公司Repligen(RGEN)今日盘中大涨9.48%,引发市场关注。这主要是由于公司新发布的2024年第四季度财报数据好于预期,带来了利好消息。\n\n根据财报显示,Repligen公司第四季度每股收益为0.44美元,超出了分析师预期的0.41美元。尽管公司当季销售额略低于预期,但盈利能力的显著提升,显示了公司良好的运营状况。\n\n分析人士认为,Repligen公司业绩超预期,增强了投资者对公司长期发展前景的信心。市场预期该公司将继续保持良好的增长动能,成为资本市场中的投资热点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179131861","title":"异动解读 | Repligen公司盘前大涨9.47%,业绩超预期带来市场利好","url":"https://stock-news.laohu8.com/highlight/detail?id=1179131861","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179131861?lang=zh_cn&edition=full","pubTime":"2025-02-20 21:54","pubTimestamp":1740059678,"startTime":"0","endTime":"0","summary":"上市生物科技公司Repligen(RGEN)今日盘前大涨9.47%,引发了市场投资者的广泛关注。\n\n消息面上,Repligen公司最新公布的2024年第四季度财报显示,公司当季每股收益为0.44美元,超出了分析师预期的0.41美元,同时公司销售额也略高于去年同期。尽管销售额低于分析师预期,但盈利能力的增长仍彰显出公司良好的运营状况。\n\n分析人士认为,Repligen公司的季度业绩好于市场预期,显示公司具有强劲的利润增长动力,这增强了投资者对公司长期前景的信心,从而刺激了公司股价在盘前大幅走高。展望未来,公司有望继续保持良好的业绩增长,成为资本市场的投资热点。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124711795","title":"Repligen 2024年第四季度调整后每股收益0.44美元,超出预期的0.41美元,销售额为1.6755亿美元,低于预期的1.6767亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1124711795","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124711795?lang=zh_cn&edition=full","pubTime":"2025-02-20 20:39","pubTimestamp":1740055154,"startTime":"0","endTime":"0","summary":"Repligen 报告其季度每股收益为0.44美元,高于分析师普遍预期的0.41美元,高出7.32%。公司报告其季度销售额为1.6755亿美元,低于分析师普遍预期的1.6767亿美元,低出0.07%。与去年同期的销售额1.6662亿美元相比,增长了0.56%。以上内容来自Benzinga Earnings专栏,原文如下:Repligen reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.41 by 7.32 percent. This is a 8.33 percent decrease over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $167.55 million which missed the analyst consensus estimate of $167.67 mill","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Repligen 2024年第四季度调整后每股收益0.44美元,超出预期的0.41美元,销售额为1.6755亿美元,低于预期的1.6767亿美元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507650584","title":"Repligen Corporation盘中异动 下午盘急速下跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507650584","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507650584?lang=zh_cn&edition=full","pubTime":"2025-01-30 03:06","pubTimestamp":1738177586,"startTime":"0","endTime":"0","summary":"北京时间2025年01月30日03时06分,Repligen Corporation股票出现波动,股价快速下挫5.10%。截至发稿,该股报165.36美元/股,成交量46.3634万股,换手率0.83%,振幅5.18%。Repligen Corporation股票所在的医疗设备行业中,整体涨幅为0.28%。Repligen Corporation公司简介:Repligen 总部位于马萨诸塞州沃尔瑟姆,是一家全球生命科学公司,开发和销售用于制造生物药物的生物加工设备和用品,包括单克隆抗体、重组蛋白、疫苗以及细胞和基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130030627a2339427&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130030627a2339427&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","LU0757428866.USD","LU1815336091.USD","RGEN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.repligen.com","stockEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0423},{"period":"6month","weight":0.5007},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.0538}],"compareEarnings":[{"period":"1week","weight":-0.039},{"period":"1month","weight":-0.0473},{"period":"3month","weight":-0.0425},{"period":"6month","weight":-0.0207},{"period":"1year","weight":0.1062},{"period":"ytd","weight":0.0708}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Repligen Corporation成立于1981年5月。该公司是生物制剂生产关键产品的领先供应商。公司根据长期供应协议为主要生命科学公司生产Protein A,同时也直接向终端用户销售产品,供其生产工艺使用。公司还将其在生物制品开发方面的专业知识应用于SecreFlo的研发。SecreFlo是公司正在开发的一种合成人激素,旨在作为一种新型显像剂用于诊断胰腺炎以及潜在的多种胰腺疾病。该公司目前还有两项针对弗里德赖希氏共济失调和脊髓性肌萎缩症的早期中枢神经系统罕见病项目正在进行中,并已进入I期临床试验阶段。此外,该公司已将部分知识产权授权给Bristol-Myers Squibb Company,并从该公司在美国销售的Orencia产品净销售额中获得特许权使用费。","yearOnYearQuotes":[{"month":1,"riseRate":0.675,"avgChangeRate":0.091484},{"month":2,"riseRate":0.4,"avgChangeRate":0.02561},{"month":3,"riseRate":0.525,"avgChangeRate":0.031522},{"month":4,"riseRate":0.5,"avgChangeRate":-0.003105},{"month":5,"riseRate":0.560976,"avgChangeRate":0.045895},{"month":6,"riseRate":0.487805,"avgChangeRate":-0.008423},{"month":7,"riseRate":0.512195,"avgChangeRate":0.029399},{"month":8,"riseRate":0.585366,"avgChangeRate":0.036134},{"month":9,"riseRate":0.390244,"avgChangeRate":-0.034091},{"month":10,"riseRate":0.463415,"avgChangeRate":0.023145},{"month":11,"riseRate":0.463415,"avgChangeRate":0.031539},{"month":12,"riseRate":0.475,"avgChangeRate":-0.003719}],"exchange":"NASDAQ","name":"Repligen Corporation","nameEN":"Repligen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Repligen Corporation(RGEN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Repligen Corporation(RGEN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Repligen Corporation,RGEN,Repligen Corporation股票,Repligen Corporation股票老虎,Repligen Corporation股票老虎国际,Repligen Corporation行情,Repligen Corporation股票行情,Repligen Corporation股价,Repligen Corporation股市,Repligen Corporation股票价格,Repligen Corporation股票交易,Repligen Corporation股票购买,Repligen Corporation股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Repligen Corporation(RGEN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Repligen Corporation(RGEN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}